FDA-cleared profile

ANDI 2.0

Imeka Solutions, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Clinical role
Quantitative visualization and segmentation aid for physician review; it does not independently diagnose or predict disease.
Images and patients
MRI · Brain
Key limitation
Keep in mind: ANDI 2.0 is adjunctive and does not diagnose or predict disease. All results require physician review. FDA validation used defined MRI sequences, sites, manufacturers and reference methods; applicability outside those conditions is not established here.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM brain MR image sets including DWI and T1 sequences within the supported acquisition and scanner scope.
  • Who uses it?Intended users: Radiologists, neurologists and other qualified healthcare professionals interpreting brain MRI.
  • What does the software produce?Output: Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.
  • What is its most important limitation?Key limitation: ANDI 2.0 is adjunctive and does not diagnose or predict disease. All results require physician review. FDA validation used defined MRI sequences, sites, manufacturers and reference methods; applicability outside those conditions is not established here.

Clinical takeaway. Clinical role: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Evidence takeaway. Evidence from the reviewed source record: FDA validation included 747 independent validation subjects across sites and manufacturers. The detailed accuracy cohort included 71 subjects with healthy, MS, Parkinson, Alzheimer and MCI cases; subcortical Dice averaged 0.89-0.96 and cortical Dice 0.79-0.93. Reproducibility testing in 59 subjects reported mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Quantitative visualization and segmentation aid for physician review; it does not independently diagnose or predict disease.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
DICOM brain MR image sets including DWI and T1 sequences within the supported acquisition and scanner scope.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Healthcare neuroimaging services using supported brain MRI protocols.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists, neurologists and other qualified healthcare professionals interpreting brain MRI.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
ANDI 2.0 is adjunctive and does not diagnose or predict disease. All results require physician review. FDA validation used defined MRI sequences, sites, manufacturers and reference methods; applicability outside those conditions is not established here.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
FDA validation included 747 independent validation subjects across sites and manufacturers. The detailed accuracy cohort included 71 subjects with healthy, MS, Parkinson, Alzheimer and MCI cases; subcortical Dice averaged 0.89-0.96 and cortical Dice 0.79-0.93. Reproducibility testing in 59 subjects reported mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA validation included 747 independent validation subjects across sites and manufacturers. The detailed accuracy cohort included 71 subjects with healthy, MS, Parkinson, Alzheimer and MCI cases; subcortical Dice averaged 0.89-0.96 and cortical Dice 0.79-0.93. Reproducibility testing in 59 subjects reported mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation and volumetric agreement measures, not disease-detection sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation and volumetric agreement measures, not disease-detection specificity.

Subcortical Dice lower bound

0.89 Dice coefficient, lower endpoint of reported range

  • EndpointSegmentation overlap
  • Population71-subject accuracy cohort within the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Subcortical Dice upper bound

0.96 Dice coefficient, upper endpoint of reported range

  • EndpointSegmentation overlap
  • Population71-subject accuracy cohort within the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Cortical Dice lower bound

0.79 Dice coefficient, lower endpoint of reported range

  • EndpointSegmentation overlap
  • Population71-subject accuracy cohort within the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Cortical Dice upper bound

0.93 Dice coefficient, upper endpoint of reported range

  • EndpointSegmentation overlap
  • Population71-subject accuracy cohort within the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Reproducibility mean absolute volume difference

2.1 percent

  • EndpointMean absolute volume difference
  • Population59-subject reproducibility cohort in the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Reproducibility individual difference lower bound

1.2 percent, lower endpoint of reported range

  • EndpointIndividual absolute volume difference
  • Population59-subject reproducibility cohort in the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

Reproducibility individual difference upper bound

3.9 percent, upper endpoint of reported range

  • EndpointIndividual absolute volume difference
  • Population59-subject reproducibility cohort in the FDA ANDI validation
  • Tested versionANDI 2.0 configuration submitted in K252298

ANDI 2.0 segmentation accuracy validation

  • DesignIndependent multi-site and multi-manufacturer validation with normative and disease cohorts; reference segmentation used FreeSurfer, expert review and three board-certified neuroradiologists
  • Population747 independent validation subjects; detailed accuracy cohort 71 subjects including healthy, MS, Parkinson, Alzheimer and MCI cases
  • Scopeexact submission
  • Tested versionANDI 2.0 configuration submitted in K252298
  • Samplen=747
  • IndependenceSponsor or vendor study

K252298

The 71-subject detailed cohort included 35 women and 36 men, ages 18-86, with the disease mix stated in the FDA summary.

ANDI 2.0 reproducibility validation

  • DesignRepeatability/reproducibility evaluation described in the FDA 510(k) summary
  • Population59-subject repeatability cohort across supported MRI conditions
  • Scopeexact submission
  • Tested versionANDI 2.0 configuration submitted in K252298
  • Samplen=59
  • IndependenceSponsor or vendor study

K252298

FDA reports mean absolute volume difference 2.1% and individual differences 1.2%-3.9%.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM brain MR image sets including DWI and T1 sequences within the supported acquisition and scanner scope.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0

  2. Routing

    Source context, not route validation: The FDA summary describes cloud or on-premises SaaS processing without a GUI and generation of reports for clinical review; local DICOM routing and viewer configuration require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0

  3. AI processing

    Source context, not route validation: Cloud or on-premises SaaS deployment described in the submission; no standalone GUI is described.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0

  4. Returned objects

    Source context, not route validation: Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0

  5. Viewer/worklist/report

    Unresolved route: Atlas-assisted visualization, automated segmentation and volumes, normative comparison and longitudinal reports for white-matter microstructure and optional gray-matter volumetry.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K252298: ANDI 2.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud or on-premises SaaS deployment described in the submission; no standalone GUI is described.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The FDA summary describes cloud or on-premises SaaS processing without a GUI and generation of reports for clinical review; local DICOM routing and viewer configuration require confirmation.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Imeka describes ANDI as a secure-cloud workflow for automated brain MRI reporting.
  • Product family
  • Checked 2026-09-06

This family statement does not establish exact K252298 controls, retention, certification or a site-specific security assessment.

Cloud or on-premises SaaS processing

The cleared submission describes cloud or on-premises SaaS processing without a GUI and generation of quantitative brain MRI reports.

exact submission · checked 2026-09-07

Automated MRI report workflow

Imeka describes ANDI as a secure-cloud workflow with a 5-8 minute single-shell sequence, support for MRI manufacturers at 1.5T or 3T, 33 fiber-tract segmentations, normative comparison and longitudinal reports.

product family · checked 2026-09-06

Family page capabilities do not establish exact K252298 availability, hosting contract or performance.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252298
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-10-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
23Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, vendor announcement, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for ANDI 2.0 was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Imeka ANDI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Only trade press (BioWorld, 2023-08-24) mentions new CPT Category III codes for quantitative brain MRI; no vendor or payer page names a code for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K252298: ANDI 2.0

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. ANDI 2.0 model card (K252298)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Get to know ANDI

    Imeka - Accessed 2026-09-06

    Scope: productFamilyContext, clinicalUse, implementationCapabilities

  8. Imeka receives FDA 510(k) clearance for ANDI 2.0

    Imeka - Accessed 2026-09-06

    Scope: productVersion, productFamilyContext

Research history

  1. K252298 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K251483

SwiftSight-Brain

AIRS Medical Inc.

Authorized purpose: Adjunctive brain MRI morphometry and lesion-quantification support for qualified healthcare professionals, including segmented overlays, volumetric measurements, normative percentiles and longitudinal comparison.

Modality
MRI
Anatomy
Brain
Decision
2025-09-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history